Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR-MPL-JAK2-STAT5 pathway.

Han L, Czech J, Maurer A, Brümmendorf TH, Chatain N, Koschmieder S.

Leukemia. 2018 Aug 8. doi: 10.1038/s41375-018-0234-6. [Epub ahead of print] No abstract available.

PMID:
30115971
2.

Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.

Isfort S, Crysandt M, Gezer D, Koschmieder S, Brümmendorf TH, Wolf D.

Recent Results Cancer Res. 2018;212:87-108. doi: 10.1007/978-3-319-91439-8_4.

PMID:
30069626
3.

Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.

Bouillon AS, Ventura Ferreira MS, Awad SA, Richter J, Hochhaus A, Kunzmann V, Dengler J, Janssen J, Ossenkoppele G, Westerweel PE, Te Boekhorst PAW, Mahon FX, Hjorth-Hansen H, Isfort S, Fioretos T, Hummel S, Schemionek M, Wilop S, Koschmieder S, Saußele S, Mustjoki S, Beier F, Brümmendorf TH.

Blood Adv. 2018 Jul 10;2(13):1572-1579. doi: 10.1182/bloodadvances.2018017772.

4.

Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells.

Lubberich RK, Walenda T, Goecke TW, Strathmann K, Isfort S, Brümmendorf TH, Koschmieder S, Wagner W.

PLoS One. 2018 May 31;13(5):e0197233. doi: 10.1371/journal.pone.0197233. eCollection 2018.

5.

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T.

Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21.

PMID:
29784639
6.

Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita.

Kirschner M, Maurer A, Wlodarski MW, Ventura Ferreira MS, Bouillon AS, Halfmeyer I, Blau W, Kreuter M, Rosewich M, Corbacioglu S, Beck J, Schwarz M, Bittenbring J, Radsak MP, Wilk CM, Koschmieder S, Begemann M, Kurth I, Schemionek M, Brümmendorf TH, Beier F.

Leukemia. 2018 Apr 2. doi: 10.1038/s41375-018-0125-x. [Epub ahead of print]

PMID:
29749397
7.

[Biobanking requirements from the perspective of the clinician : Experiences in hematology and oncology].

Koschmieder S, Brümmendorf TH.

Pathologe. 2018 Jul;39(4):303-307. doi: 10.1007/s00292-018-0434-x. Review. German.

PMID:
29623404
8.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G.

Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Review.

PMID:
29515238
9.

Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.

He L, Tang J, Andersson EI, Timonen S, Koschmieder S, Wennerberg K, Mustjoki S, Aittokallio T.

Cancer Res. 2018 May 1;78(9):2407-2418. doi: 10.1158/0008-5472.CAN-17-3644. Epub 2018 Feb 26.

PMID:
29483097
10.

Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O.

Leuk Res. 2018 Apr;67:67-74. doi: 10.1016/j.leukres.2018.02.008. Epub 2018 Feb 14. Review.

PMID:
29466766
11.

Bone marrow laminins influence hematopoietic stem and progenitor cell cycling and homing to the bone marrow.

Susek KH, Korpos E, Huppert J, Wu C, Savelyeva I, Rosenbauer F, Müller-Tidow C, Koschmieder S, Sorokin L.

Matrix Biol. 2018 Apr;67:47-62. doi: 10.1016/j.matbio.2018.01.007. Epub 2018 Jan 31.

PMID:
29360499
12.

Leukocyte Counts Based on DNA Methylation at Individual Cytosines.

Frobel J, Božić T, Lenz M, Uciechowski P, Han Y, Herwartz R, Strathmann K, Isfort S, Panse J, Esser A, Birkhofer C, Gerstenmaier U, Kraus T, Rink L, Koschmieder S, Wagner W.

Clin Chem. 2018 Mar;64(3):566-575. doi: 10.1373/clinchem.2017.279935. Epub 2017 Nov 8.

PMID:
29118064
13.

Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.

Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T.

Blood. 2017 Dec 28;130(26):2848-2859. doi: 10.1182/blood-2017-05-784942. Epub 2017 Oct 17.

PMID:
29042365
14.

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Andersson EI, Pützer S, Yadav B, Dufva O, Khan S, He L, Sellner L, Schrader A, Crispatzu G, Oleś M, Zhang H, Adnan-Awad S, Lagström S, Bellanger D, Mpindi JP, Eldfors S, Pemovska T, Pietarinen P, Lauhio A, Tomska K, Cuesta-Mateos C, Faber E, Koschmieder S, Brümmendorf TH, Kytölä S, Savolainen ER, Siitonen T, Ellonen P, Kallioniemi O, Wennerberg K, Ding W, Stern MH, Huber W, Anders S, Tang J, Aittokallio T, Zenz T, Herling M, Mustjoki S.

Leukemia. 2018 Mar;32(3):774-787. doi: 10.1038/leu.2017.252. Epub 2017 Aug 14.

PMID:
28804127
15.

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.

Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA.

Ann Hematol. 2017 Oct;96(10):1653-1665. doi: 10.1007/s00277-017-3082-y. Epub 2017 Aug 5.

16.

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options.

Koschmieder S, Vetrie D.

Semin Cancer Biol. 2018 Aug;51:180-197. doi: 10.1016/j.semcancer.2017.07.006. Epub 2017 Aug 2. Review.

17.

Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature.

Jennes E, Guggenberger D, Zotz R, Thompson L, Brümmendorf TH, Koschmieder S, Jost E.

Clin Case Rep. 2017 Mar 30;5(5):664-670. doi: 10.1002/ccr3.890. eCollection 2017 May.

18.

The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients.

Schubert C, Chatain N, Braunschweig T, Schemionek M, Feldberg K, Hoffmann M, Dufva O, Mustjoki S, Brümmendorf TH, Koschmieder S.

Oncotarget. 2017 May 23;8(21):34736-34749. doi: 10.18632/oncotarget.16152.

19.

Mtss1(CSC156) mutant mice fail to display efficient Mtss1 protein depletion.

Fahrenkamp D, Herrmann O, Koschmieder S, Brümmendorf TH, Schemionek M.

Leukemia. 2017 Apr;31(4):1017-1019. doi: 10.1038/leu.2017.19. Epub 2017 Feb 7. No abstract available.

PMID:
28167834
20.

Modelling IRF8 Deficient Human Hematopoiesis and Dendritic Cell Development with Engineered iPS Cells.

Sontag S, Förster M, Qin J, Wanek P, Mitzka S, Schüler HM, Koschmieder S, Rose-John S, Seré K, Zenke M.

Stem Cells. 2017 Apr;35(4):898-908. doi: 10.1002/stem.2565. Epub 2017 Feb 1.

21.

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).

Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, Koschmieder S, Rinaldi C, Byrne J, Hasan Y, Passamonti F, Verstovsek S, Hunter D, Jones MM, Zhen H, Habr D, Martino B.

Br J Haematol. 2017 Jan;176(1):76-85. doi: 10.1111/bjh.14382. Epub 2016 Nov 8.

22.

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.

Ben-Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus JL, Rankin S, Clark RE, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf TH, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason GV, Holyoake TL, Loges S.

Clin Cancer Res. 2017 May 1;23(9):2289-2300. doi: 10.1158/1078-0432.CCR-16-1930. Epub 2016 Nov 17.

23.

Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization.

Fahrenkamp D, Li J, Ernst S, Schmitz-Van de Leur H, Chatain N, Küster A, Koschmieder S, Lüscher B, Rossetti G, Müller-Newen G.

Sci Rep. 2016 Oct 18;6:35454. doi: 10.1038/srep35454.

24.

Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.

Kaifie A, Isfort S, Gattermann N, Hollburg W, Klausmann M, Wolf D, Maintz C, Hänel M, Goekkurt E, Göthert JR, Platzbecker U, Geer T, Parmentier S, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL).

Ann Hematol. 2016 Sep;95(9):1399-410. doi: 10.1007/s00277-016-2730-y. Epub 2016 Jun 22.

PMID:
27334946
25.

Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.

Mughal TI, Abdel-Wahab O, Rampal R, Mesa R, Koschmieder S, Levine R, Hehlmann R, Saglio G, Barbui T, Van Etten RA.

Leuk Lymphoma. 2016 Jul;57(7):1517-26. doi: 10.1080/10428194.2016.1185783. Epub 2016 May 31. Review.

26.

γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.

Görtzen J, Hunka LM, Vonnahme M, Praktiknjo M, Kaifie A, Fimmers R, Jansen C, Heine A, Lehmann J, Goethert JR, Gattermann N, Goekkurt E, Platzbecker U, Brossart P, Strassburg CP, Brummendorf TH, Koschmieder S, Wolf D, Trebicka J.

Medicine (Baltimore). 2016 May;95(20):e3355. doi: 10.1097/MD.0000000000003355.

27.

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.

Han L, Schubert C, Köhler J, Schemionek M, Isfort S, Brümmendorf TH, Koschmieder S, Chatain N.

J Hematol Oncol. 2016 May 13;9(1):45. doi: 10.1186/s13045-016-0275-0.

28.

Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model.

Halbach S, Köhler M, Uhl FM, Huber J, Zeiser R, Koschmieder S, Aumann K, Brummer T.

Leukemia. 2016 Sep;30(9):1942-5. doi: 10.1038/leu.2016.92. Epub 2016 Apr 29. No abstract available.

PMID:
27125306
29.

BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance.

Weiland J, Pal D, Case M, Irving J, Ponthan F, Koschmieder S, Heidenreich O, von Stackelberg A, Eckert C, Vormoor J, Elder A.

Leukemia. 2016 Sep;30(9):1920-3. doi: 10.1038/leu.2016.64. Epub 2016 Mar 17. No abstract available.

30.

Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia.

Brehme M, Koschmieder S, Montazeri M, Copland M, Oehler VG, Radich JP, Brümmendorf TH, Schuppert A.

Sci Rep. 2016 Apr 6;6:24057. doi: 10.1038/srep24057.

31.

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.

Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W, Göthert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL).

J Hematol Oncol. 2016 Mar 5;9:18. doi: 10.1186/s13045-016-0242-9.

32.

Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).

Appelmann I, Kreher S, Parmentier S, Wolf HH, Bisping G, Kirschner M, Bergmann F, Schilling K, Brümmendorf TH, Petrides PE, Tiede A, Matzdorff A, Griesshammer M, Riess H, Koschmieder S.

Ann Hematol. 2016 Apr;95(5):707-18. doi: 10.1007/s00277-016-2621-2. Epub 2016 Feb 26. Review.

PMID:
26916570
33.

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL, Hehlmann R, Maria Vannucchi A, Cervantes F, Silver RT, Barbui T.

Leukemia. 2016 May;30(5):1018-24. doi: 10.1038/leu.2016.12. Epub 2016 Feb 8. Review.

PMID:
26854026
34.

[Diagnosis and treatment of polycythemia vera in the year 2015].

Lengfelder E, Griesshammer M, Koschmieder S.

Dtsch Med Wochenschr. 2015 Oct;140(20):e256. doi: 10.1055/s-0041-110562. Epub 2015 Dec 4. German. No abstract available.

PMID:
26636622
35.

Mtss1 is a critical epigenetically regulated tumor suppressor in CML.

Schemionek M, Herrmann O, Reher MM, Chatain N, Schubert C, Costa IG, Hänzelmann S, Gusmao EG, Kintsler S, Braunschweig T, Hamilton A, Helgason GV, Copland M, Schwab A, Müller-Tidow C, Li S, Holyoake TL, Brümmendorf TH, Koschmieder S.

Leukemia. 2016 Apr;30(4):823-32. doi: 10.1038/leu.2015.329. Epub 2015 Dec 1.

PMID:
26621336
36.

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.

Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U; Study Alliance Leukemia Group.

Leukemia. 2016 Mar;30(3):555-61. doi: 10.1038/leu.2015.306. Epub 2015 Nov 2.

PMID:
26522083
37.

[Diagnosis and treatment of polycythemia vera in 2015].

Lengfelder E, Griesshammer M, Koschmieder S.

Dtsch Med Wochenschr. 2015 Oct;140(20):1501-6. doi: 10.1055/s-0041-103336. Epub 2015 Oct 7. German. No abstract available. Erratum in: Dtsch Med Wochenschr. 2015 Oct;140(20):e256.

PMID:
26445252
38.

Cancer Screening in Patients with Idiopathic Venous Thromboembolism--a Position Paper of the German Society of Hematology and Oncology Working Group on Hemostasis.

Matzdorff A, Riess H, Bergmann F, Bisping G, Koschmieder S, Parmentier S, Petrides PE, Sosada M.

Oncol Res Treat. 2015;38(9):454-8. doi: 10.1159/000437451. Epub 2015 Aug 5. Review.

PMID:
26407062
39.

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.

Wenn K, Tomala L, Wilop S, Vankann L, Hasenbank C, Frank O, Hochhaus A, Giles FJ, Lange T, Müller MC, Koschmieder S, Beier F, Ziegler P, Brümmendorf TH.

Leukemia. 2015 Dec;29(12):2402-4. doi: 10.1038/leu.2015.245. Epub 2015 Sep 15. No abstract available.

PMID:
26369986
40.

A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.

Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan WI, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ, Huntly BJ.

J Exp Med. 2015 Sep 21;212(10):1551-69. doi: 10.1084/jem.20141661. Epub 2015 Aug 24.

41.

A Limited Role for the Cell Cycle Regulator Cyclin A1 in Murine Leukemogenesis.

Bäumer N, Bäumer S, Haak M, Koschmieder S, Schönig K, Berdel WE, Müller-Tidow C.

PLoS One. 2015 Jun 16;10(6):e0129147. doi: 10.1371/journal.pone.0129147. eCollection 2015.

42.

Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine.

Chatain N, Perera RC, Rossetti G, Rossa J, Carloni P, Schemionek M, Haferlach T, Brümmendorf TH, Schnittger S, Koschmieder S.

Leukemia. 2015 Dec;29(12):2434-8. doi: 10.1038/leu.2015.131. Epub 2015 May 27. No abstract available.

PMID:
26012842
43.

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia.

Schemionek M, Kharabi Masouleh B, Klaile Y, Krug U, Hebestreit K, Schubert C, Dugas M, Büchner T, Wörmann B, Hiddemann W, Berdel WE, Brümmendorf TH, Müller-Tidow C, Koschmieder S.

PLoS One. 2015 May 21;10(5):e0125783. doi: 10.1371/journal.pone.0125783. eCollection 2015.

44.

Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.

Kirschner MM, Schemionek M, Schubert C, Chatain N, Sontag S, Isfort S, Ortiz-Brüchle N, Schmitt K, Krüger L, Zerres K, Zenke M, Brümmendorf TH, Koschmieder S.

PLoS One. 2015 Apr 20;10(4):e0123476. doi: 10.1371/journal.pone.0123476. eCollection 2015.

45.

JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.

Schönberg K, Rudolph J, Vonnahme M, Parampalli Yajnanarayana S, Cornez I, Hejazi M, Manser AR, Uhrberg M, Verbeek W, Koschmieder S, Brümmendorf TH, Brossart P, Heine A, Wolf D.

Cancer Res. 2015 Jun 1;75(11):2187-99. doi: 10.1158/0008-5472.CAN-14-3198. Epub 2015 Apr 1.

46.

CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia.

Weiland J, Elder A, Forster V, Heidenreich O, Koschmieder S, Vormoor J.

Pediatr Blood Cancer. 2015 Jul;62(7):1144-8. doi: 10.1002/pbc.25462. Epub 2015 Mar 8. Review.

PMID:
25755168
47.

Epigenetic biomarker to support classification into pluripotent and non-pluripotent cells.

Lenz M, Goetzke R, Schenk A, Schubert C, Veeck J, Hemeda H, Koschmieder S, Zenke M, Schuppert A, Wagner W.

Sci Rep. 2015 Mar 10;5:8973. doi: 10.1038/srep08973.

48.

Drug target optimization in chronic myeloid leukemia using innovative computational platform.

Chuang R, Hall BA, Benque D, Cook B, Ishtiaq S, Piterman N, Taylor A, Vardi M, Koschmieder S, Gottgens B, Fisher J.

Sci Rep. 2015 Feb 3;5:8190. doi: 10.1038/srep08190.

49.

Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms.

Schneider RK, Ziegler S, Leisten I, Ferreira MS, Schumacher A, Rath B, Fahrenkamp D, Müller-Newen G, Crysandt M, Wilop S, Jost E, Koschmieder S, Knüchel R, Brümmendorf TH, Ziegler P.

J Hematol Oncol. 2014 Dec 14;7:92. doi: 10.1186/s13045-014-0092-2.

50.

Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.

Kaeda J, Ringel F, Oberender C, Mills K, Quintarelli C, Pane F, Koschmieder S, Slany R, Schwarzer R, Saglio G, Hemmati P, van Lessen A, Amini L, Gresse M, Vagge E, Burmeister T, Serra A, Carson A, Schwarz M, Westermann J, Jundt F, Dörken B, le Coutre P.

Leuk Lymphoma. 2015 Jul;56(7):2105-13. doi: 10.3109/10428194.2014.981175. Epub 2015 Jan 23.

PMID:
25363400

Supplemental Content

Loading ...
Support Center